Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL66021 | 0.98 | ALDH1A1 (0.54) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL22261569 | 0.94 | ALDH1A1 (0.46) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL21513122 | 0.92 | ALDH1A1 (0.45) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL10257448 | 0.91 | ALDH1A1 (0.48) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL13756007 | 0.91 | CYP1A2 (0.52) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL13755913 | 0.90 | CYP1A2 (0.57) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL7866486 | 0.90 | CYP1A2 (0.57) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL64281 | 0.89 | ALDH1A1 (0.46) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL20937027 | 0.89 | CYP1A2 (0.50) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL64362 | 0.89 | ALDH1A1 (0.46) | ALDH1A1TRPA1GAAMGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| US-12037617-B2 | Methods and compositions for modulating a genome | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037602-B2 | Methods and compositions for modulating a genome | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12006440-B2 | Radiation curable inkjet inks for interior decoration | AGFA NV (BE) | 2024-06-11 | — | — | US | disclosed |
| US-20240026324-A1 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2024-01-25 | — | — | US | disclosed |
| US-20240018551-A1 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2024-01-18 | — | — | US | disclosed |
| US-20220119656-A1 | RADIATION CURABLE INKJET INKS FOR INTERIOR DECORATION | AGFA NV (BE) | 2022-04-21 | — | — | US | disclosed |
| US-20220119656-A1 | RADIATION CURABLE INKJET INKS FOR INTERIOR DECORATION | AGFA NV (BE) | 2022-04-21 | — | — | US | disclosed |
| EP-3686251-B1 | RADIATION CURABLE INKJET INKS FOR INTERIOR DECORATION | AGFA NV (BE) | 2021-11-17 | — | — | EP | disclosed |
| WO-2020152243-A1 | RADIATION CURABLE INKJET INKS FOR INTERIOR DECORATION | AGFA NV (BE) | 2020-07-30 | — | — | WO | disclosed |
| EP-3686251-A1 | RADIATION CURABLE INKJET INKS FOR INTERIOR DECORATION | AGFA NV (BE) | 2020-07-29 | — | — | EP | disclosed |
| US-7960305-B2 | a mixture of a phosphazenium compound such as tetrakis[tris(dimethylamino)phosphoranylideneamino]phosphonium chloride, transition metal halides and an organic halogen compound as an activator, used for addition homo/copolymerization; living polymers | MITSUI CHEMICALS, INC. (JP) | 2011-06-14 | — | — | US | disclosed |
| WO-2009097332-A2 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20080177014-A1 | Polymerization Catalyst Composition and Process for Production of Polymer | MITSUI CHEMICALS, INC. (JP) | 2008-07-24 | — | — | US | disclosed |
| EP-1857471-A1 | POLYMERIZATION CATALYST COMPOSITION AND PROCESS FOR PRODUCTION OF POLYMER | Mitsui Chemicals, Inc. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | ALDH1A1 2999/4885TRPA1 2979/4885GAA 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.